Extended Access of Momelotinib in Adults With Myelofibrosis
This study is designed for adults with a type of bone marrow disorder called myelofibrosis (including primary myelofibrosis, or after polycythemia vera or essential thrombocythemia). It's an opportunity for people who are already taking a medication called momelotinib in certain previous studies and are doing well on it to continue their treatment. The main goal is to keep an eye on how safe momelotinib is over a longer period. Researchers will also look at how it might affect how long people live and whether it helps prevent the illness from turning into leukaemia. This helps ensure patients who are benefiting can continue their current care.
At a glance
What is this study about?
This research study is about a medicine called momelotinib. It's particularly for adults who have a bone marrow condition known as myelofibrosis. Myelofibrosis causes scar tissue to build up in the bone marrow, which can affect the body's ability to make healthy blood cells.
The main purpose of this study is to allow people who are already taking momelotinib in other ongoing studies to continue receiving the treatment. This is important because it means patients who are finding the medication helpful can keep taking it, rather than having to stop. The medical team will carefully watch to see if momelotinib continues to be safe for them over a longer time.
Beyond safety, the study will also look at how momelotinib affects people’s overall health and how long they live. Researchers will also be checking if it helps reduce the risk of myelofibrosis progressing to leukaemia, which is a more serious type of blood cancer. This helps us understand the long-term benefits of the treatment.
Key takeaways
- This study is an extension for people already on momelotinib for myelofibrosis.
- It aims to check the long-term safety of momelotinib.
- Researchers will also look at overall survival and leukaemia-free survival.
- You must be an adult already taking part in a specific momelotinib study.
- You cannot join if you are allergic to momelotinib.
Who may be eligible?
This study is for adults who are already taking part in specific previous research studies involving momelotinib. You must be currently receiving momelotinib treatment in one of these studies and it must be helping you, meaning your illness hasn't gotten worse while on the medication.
To be considered, you need to be able to understand what the study involves and be willing to sign a consent form, which shows you agree to take part. You must be at least 18 years old.
Hover, you cannot join this study if you've had a bad reaction or are very sensitive to momelotinib or any of its ingredients in the past. Your doctor or the study team will be able to check all the specific details to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you currently taking momelotinib in one of the specific previous studies?
- Is momelotinib currently helping your myelofibrosis, meaning your disease hasn't gotten worse?
- Are you 18 years old or older?
- Have you ever had a severe allergic reaction to momelotinib or any of its ingredients?
What does participation involve?
As this an extension study, if you are eligible, you would continue to take momelotinib medication, which comes in tablet form (50mg, 100mg, 150mg, or 200mg strengths). The frequency of your visits to the clinic will be determined by the study team to monitor your health and the effects of the medication. These visits will involve various tests and check-ups to assess your safety and how well the treatment is working. The total duration for how long you will participate in this extended access program will depend on your individual response to the treatment and the study's overall plan.
Potential risks and benefits
Locations (112)
- GSK Investigational SiteVerified postcodeScottsdale, United States
- GSK Investigational SiteVerified postcodeOrange, United States
- GSK Investigational SiteVerified postcodeStanford, United States
- GSK Investigational SiteVerified postcodeAurora, United States
- GSK Investigational SiteVerified postcodeJacksonville, United States
- GSK Investigational SiteVerified postcodeTampa, United States
- GSK Investigational SiteVerified postcodeAtlanta, United States
- GSK Investigational SiteVerified postcodeBaltimore, United States
- GSK Investigational SiteVerified postcodeBoston, United States
- GSK Investigational SiteVerified postcodeRochester, United States
- GSK Investigational SiteVerified postcodeSt Louis, United States
- GSK Investigational SiteVerified postcodeHackensack, United States
Common questions
What is myelofibrosis?
Myelofibrosis is a condition where scar tissue builds up in your bone marrow, affecting its ability to make healthy blood cells.
What is momelotinib?
Momelotinib is a medication being studied for its effects on myelofibrosis. It comes in different strength tablets.
Who can join this study?
This study is mainly for adults who are already taking momelotinib in specific previous studies and are doing well on the treatment.
What happens if I join?
You would continue taking momelotinib, and the study team would regularly check your health and how the medicine is affecting you.
Can I stop taking part in the study?
Yes, you can choose to leave the study at any time, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.